ROIVANT SCIENCES LTD. Other Noncash Income (Expense)
ROIVANT SCIENCES LTD. (ROIV) reported Other Noncash Income (Expense) of -$9.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-06
- ROIVANT SCIENCES LTD. other noncash income (expense) for the quarter ending 2026-06-30 was -$9.79M.
- ROIVANT SCIENCES LTD. other noncash income (expense) for the quarter ending 2026-03-31 was $5.52M.
- ROIVANT SCIENCES LTD. other noncash income (expense) for the quarter ending 2025-12-31 was $9.72M.
- ROIVANT SCIENCES LTD. other noncash income (expense) for the quarter ending 2025-09-30 was -$5.98M, a 133.34% decline year-over-year.
- ROIVANT SCIENCES LTD. other noncash income (expense) for fiscal 2026 was -$1.83M.
- ROIVANT SCIENCES LTD. other noncash income (expense) for fiscal 2025 was -$3.76M.
- ROIVANT SCIENCES LTD. other noncash income (expense) for fiscal 2024 was -$10.25M, a 148.33% decline from fiscal 2023.
- ROIVANT SCIENCES LTD. other noncash income (expense) for fiscal 2023 was $21.21M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month | Other Noncash Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$9.79M 10-Q · filed 2026-08-06 | -$4.27M derived: sum of 2 quarters · filed 2026-08-06 | $5.45M derived: sum of 3 quarters · filed 2026-08-06 | -$535.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $5.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $15.23M derived: sum of 2 quarters · filed 2026-05-20 | $9.25M derived: sum of 3 quarters · filed 2026-05-20 | -$1.83M 10-K · filed 2026-05-20 | ||||
| 2025-12-31 | $9.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $3.74M derived: sum of 2 quarters · filed 2026-02-06 | -$7.34M 10-Q · filed 2026-02-06 | -$11.57M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-09-30 | -$5.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$17.06M 10-Q · filed 2025-11-10 | -$21.29M derived: sum of 3 quarters · filed 2026-08-06 | -$33.18M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$11.08M 10-Q · filed 2026-08-06 | -$15.31M derived: sum of 2 quarters · filed 2026-08-06 | -$27.20M derived: sum of 3 quarters · filed 2026-08-06 | -$9.27M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$16.12M derived: sum of 2 quarters · filed 2026-05-20 | $1.81M derived: sum of 3 quarters · filed 2026-05-20 | -$3.76M 10-K · filed 2026-05-20 | ||||
| 2024-12-31 | -$11.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $6.04M derived: sum of 2 quarters · filed 2026-02-06 | $465.00K 10-Q · filed 2026-02-06 | -$41.63M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-09-30 | $17.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $12.36M 10-Q · filed 2025-11-10 | -$29.73M derived: sum of 3 quarters · filed 2026-05-20 | $7.41M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-06-30 | -$5.58M 10-Q · filed 2025-08-11 | -$47.67M derived: sum of 2 quarters · filed 2026-05-20 | -$10.53M derived: sum of 3 quarters · filed 2026-05-20 | -$21.46M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-03-31 | -$42.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$4.95M derived: sum of 2 quarters · filed 2026-05-20 | -$15.89M derived: sum of 3 quarters · filed 2026-05-20 | -$10.25M 10-K · filed 2026-05-20 | ||||
| 2023-12-31 | $37.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | $26.21M derived: sum of 2 quarters · filed 2025-02-10 | $31.85M 10-Q · filed 2025-02-10 | $44.99M derived: sum of 4 quarters · filed 2025-05-29 | ||||
| 2023-09-30 | -$10.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | -$5.29M 10-Q · filed 2024-11-12 | $7.84M derived: sum of 3 quarters · filed 2025-05-29 | $24.63M derived: sum of 4 quarters · filed 2025-05-29 | ||||
| 2023-06-30 | $5.64M 10-Q · filed 2024-08-09 | $18.78M derived: sum of 2 quarters · filed 2025-05-29 | $35.56M derived: sum of 3 quarters · filed 2025-05-29 | $33.43M derived: sum of 4 quarters · filed 2025-05-29 | ||||
| 2023-03-31 | $13.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $29.92M derived: sum of 2 quarters · filed 2025-05-29 | $27.79M derived: sum of 3 quarters · filed 2025-05-29 | $21.21M 10-K · filed 2025-05-29 | ||||
| 2022-12-31 | $16.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | $14.65M derived: sum of 2 quarters · filed 2024-02-13 | $8.07M 10-Q · filed 2024-02-13 | $6.29M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-09-30 | -$2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | -$8.72M 10-Q · filed 2023-11-13 | -$10.49M derived: sum of 3 quarters · filed 2023-11-13 | -$8.57M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | -$6.58M 10-Q · filed 2023-08-14 | -$11.26M 10-Q · filed 2022-08-15 | -$8.36M derived: sum of 2 quarters · filed 2023-08-14 | -$6.44M derived: sum of 3 quarters · filed 2023-08-14 | -$6.36M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $141.00K derived: sum of 2 quarters · filed 2023-06-28 | $221.00K derived: sum of 3 quarters · filed 2023-06-28 | -$617.00K 10-K · filed 2023-06-28 | -$13.82M 10-K · filed 2022-06-28 | |||
| 2021-12-31 | $1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | $2.00M derived: sum of 2 quarters · filed 2023-02-13 | $1.16M 10-Q · filed 2023-02-13 | -$8.47M 10-Q · filed 2022-02-14 | -$13.42M derived: sum of 4 quarters · filed 2023-02-13 | |||
| 2021-09-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | -$758.00K 10-Q · filed 2022-11-14 | -$7.27M 10-Q · filed 2021-11-15 | -$15.34M derived: sum of 3 quarters · filed 2022-11-14 | -$11.98M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | -$838.00K 10-Q · filed 2022-08-15 | -$15.42M derived: sum of 2 quarters · filed 2022-08-15 | -$12.06M derived: sum of 3 quarters · filed 2022-08-15 | -$14.51M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | -$14.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | -$11.22M derived: sum of 2 quarters · filed 2022-06-28 | -$13.67M derived: sum of 3 quarters · filed 2022-06-28 | -$16.98M 10-K · filed 2022-06-28 | ||||
| 2020-12-31 | $3.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-14 | $909.00K derived: sum of 2 quarters · filed 2022-02-14 | -$2.40M 10-Q · filed 2022-02-14 | |||||
| 2020-09-30 | -$2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-15 | -$5.75M 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | -$3.31M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |